{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:36:41Z","timestamp":1791247001392,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T00:00:00Z","timestamp":1396396800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013586","name":"Ahmanson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013586","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jacc.2012.12.022","type":"journal-article","created":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T18:10:36Z","timestamp":1361383836000},"page":"1440-1446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Incremental Cost-Effectiveness of Guideline-Directed Medical Therapies for Heart Failure"],"prefix":"10.1016","volume":"61","author":[{"given":"Gaurav","family":"Banka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2012.12.022_bib1","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.12.022_bib2","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.12.022_bib3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.amjcard.2007.11.061","article-title":"Heart failure incidence and survival (from the atherosclerosis risk in communities study)","volume":"101","author":"Loehr","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.12.022_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1471-2407-10-105","article-title":"Long-term survival of cancer patients compared to heart failure and stroke: a systematic review","volume":"10","author":"Askoxylakis","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jacc.2012.12.022_bib5","first-page":"e46","article-title":"Heart disease and stroke statistics\u20132010 update: a report from the American Heart Association","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.12.022_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.12.022_bib7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol Cr\/Xl randomized intervention trial in congestive heart failure","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2012.12.022_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.12.022_bib9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1071-9164(05)80006-5","article-title":"Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of left ventricular dysfunction treatment trial","volume":"1","author":"Glick","year":"1995","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2012.12.022_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14240","article-title":"A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure","volume":"14","author":"McKenna","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jacc.2012.12.022_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1067\/mhj.2001.116479","article-title":"Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada","volume":"142","author":"Levy","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2012.12.022_bib12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/11585990-000000000-00000","article-title":"Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review","volume":"29","author":"Goehler","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jacc.2012.12.022_bib13","doi-asserted-by":"crossref","first-page":"74S","DOI":"10.1016\/S0002-9343(98)00387-8","article-title":"Economic impact of beta blockade in heart failure","volume":"110","author":"Gregory","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2012.12.022_bib14","first-page":"1","article-title":"United States life tables, 2007","author":"Arias","year":"2011"},{"key":"10.1016\/j.jacc.2012.12.022_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0002-9149(98)01066-2","article-title":"Cost effectiveness of carvedilol for heart Failure","volume":"83","author":"Delea","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.12.022_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-7525-8-13","article-title":"A review of health utilities using the Eq-5d in studies of cardiovascular disease","volume":"8","author":"Dyer","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jacc.2012.12.022_bib20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1023\/A:1015371616135","article-title":"Economic evaluation of the randomized aldactone evaluation study: treatment of patients with severe heart failure","volume":"16","author":"Glick","year":"2002","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2012.12.022_bib21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.pec.2005.04.005","article-title":"Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial","volume":"61","author":"Ekman","year":"2006","journal-title":"Patient Educ Couns"},{"key":"10.1016\/j.jacc.2012.12.022_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","article-title":"Willingness to pay for a quality-adjusted life year: in search of a standard","volume":"20","author":"Hirth","year":"2000","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jacc.2012.12.022_bib23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ahj.2007.10.001","article-title":"Heart failure disease management programs: a cost-effectiveness analysis","volume":"155","author":"Chan","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2012.12.022_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3945\/ajcn.110.004622","article-title":"The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010?","volume":"93","author":"Astrup","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jacc.2012.12.022_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ahj.2004.09.023","article-title":"Metaanalysis and review of heart failure disease management randomized controlled clinical trials","volume":"149","author":"Whellan","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2012.12.022_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/HPC.0b013e31812da7ed","article-title":"Improved treatment of hospitalized coronary artery disease patients with the get with the guidelines program","volume":"6","author":"LaBresh","year":"2007","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.jacc.2012.12.022_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ahj.2009.11.002","article-title":"Are quality improvements associated with the get with the guidelines-coronary artery disease program sustained over time?","volume":"159","author":"Xian","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2012.12.022_bib28","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1592\/phco.26.8.1157","article-title":"Drug copayment and adherence in chronic heart failure: effect on cost and outcomes","volume":"26","author":"Cole","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2012.12.022_bib29","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","article-title":"Full coverage for preventive medications after myocardial infarction","volume":"365","author":"Choudhry","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.12.022_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-6296(96)00506-1","article-title":"Economic foundations of cost-effectiveness analysis","volume":"16","author":"Garber","year":"1997","journal-title":"J Health Econ"},{"key":"10.1016\/j.jacc.2012.12.022_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jhealeco.2007.09.011","article-title":"Future costs in cost effectiveness analysis","volume":"27","author":"Lee","year":"2008","journal-title":"J Health Econ"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:57:39Z","timestamp":1760014659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0735109713000405"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2012.12.022","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incremental Cost-Effectiveness of Guideline-Directed Medical Therapies for Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2012.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}